Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:Inhibition of paclitaxel stimulated- P-gp ATPase activity (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:As such, the compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profili...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Servic...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 1.10nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 1.80nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Servic...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using I...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:As such, the compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profili...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.40nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.5nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetRAF proto-oncogene serine/threonine-protein kinase [Y340D,Y341D](Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 2.80nMAssay Description:The compounds prepared in Examples were tested for inhibitory activities against three subtypes of RAF, i.e. RAF1 Y340D Y341D, BRAF normal type and B...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Antagonist activity at recombinant human N-terminal His6-tagged FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells using I...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Hanmi Pharm.
US Patent
Hanmi Pharm.
US Patent
Affinity DataIC50: 3.60nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Affinity DataIC50: 3.70nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured. Th...More data for this Ligand-Target Pair
Affinity DataIC50: 3.70nMAssay Description:The inhibitory activity of some of the compounds described above against FLT3-ITD, FLT3 wild type (WT), VEGFR2 (KDR), and SYK kinase was measured.The...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:As such, the compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profili...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profiling Servic...More data for this Ligand-Target Pair
Affinity DataIC50: 4.90nMAssay Description:Inhibition of paclitaxel stimulated- P-gp ATPase activity (unknown origin)More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:As such, the compounds prepared in Examples were tested for inhibitory activity against FMS, DDR1 and DDR2 kinases using Kinase Screening and Profili...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The compounds prepared in Examples were tested for inhibitory activity against three subtypes of RAF, i.e., RAF1 Y340D Y341D (C-RAF), B-RAF normal ty...More data for this Ligand-Target Pair